A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants

NCT03232983 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: LY900014 (SC)
DRUG: LY900014 (IV)

Sponsor

Eli Lilly and Company